(Circulation. 1999;99:81-89.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Is 
-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery?
A Meta-Analysis
From the Departments of Surgery (J.J.M., N.J.O.B., J.D.B., L.J.D.) and Medicine (G.T.O.), Center for the Evaluative Clinical Sciences (G.T.O., J.D.B.), Dartmouth Medical School, Hanover, NH, and the VA Outcomes Group (J.J.M., J.D.B.), Veterans Affairs Medical Center, White River Junction, Vt.
Background—Although aprotinin is
known to be effective in reducing postoperative hemorrhage
after cardiac surgery, 
-aminocaproic acid, an alternative
antifibrinolytic, is considerably less expensive. Because the results
of 3 small randomized clinical trials comparing these 2 agents directly
were inconclusive, we performed a meta-analysis to compare the
relative effectiveness and adverse-effect profile of these 2 agents
against placebo.
Methods and Results—Data from 52 randomized clinical trials
published between 1985 and 1998 involving the use of -aminocaproic
acid (n=9) or aprotinin (n=46) in patients undergoing cardiac surgery
were abstracted. Our primary outcomes were total blood loss, red blood
cell transfusion rates and amounts, reexploration, stroke, myocardial
infarction, and mortality. The meta-analysis revealed
substantial reductions in total blood loss with -aminocaproic acid
and low-dose aprotinin (each with a 35% reduction versus placebo,
P<0.001) and high-dose aprotinin (53% reduction,
P<0.001). There were identical reductions in total
postoperative transfusions with -aminocaproic acid (61% reduction
versus placebo, P<0.010) and high-dose aprotinin (62%
reduction, P<0.001). The proportion of patients
transfused was similarly reduced with -aminocaproic acid (OR, 0.32;
95% CI, 0.15 to 0.69) and high-dose aprotinin (OR, 0.28; 0.22 to
0.37). Although both drugs reduced rates of reexploration to similar
degrees, this effect was statistically significant only with high-dose
aprotinin (OR, 0.39; 0.24 to 0.61). -Aminocaproic acid and aprotinin
had no effect on risks of postoperative myocardial infarction or
overall mortality.
Conclusions—Because the 2 antifibrinolytic agents appear to have
similar efficacies, the considerably less-expensive -aminocaproic
acid may be preferred over aprotinin for reducing hemorrhage
with cardiac surgery.
Key Words: -aminocaproic acid • aprotinin • hemorrhage • meta-analysis • surgery
This article has been cited by other articles:
 |
|
 |
|
  S. C. Stamou, M. K. Reames, E. Skipper, R. M. Stiegel, M. Nussbaum, R. Geller, F. Robicsek, and K. W. Lobdell Aprotinin in cardiac surgery patients: is the risk worth the benefit? Eur. J. Cardiothorac. Surg., November 1, 2009; 36(5): 869 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. McIlroy, P. S. Myles, L. E. Phillips, and J. A. Smith Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis Br. J. Anaesth., February 1, 2009; 102(2): 168 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Henry MBChB, P. Carless BHSc MMedS, D. Fergusson PhD MHA, and A. Laupacis MD MSc The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis Can. Med. Assoc. J., January 20, 2009; 180(2): 183 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Martin, G. Wiesner, T. Breuer, R. Lange, and P. Tassani The Risks of Aprotinin and Tranexamic Acid in Cardiac Surgery: A One-Year Follow-Up of 1188 Consecutive Patients Anesth. Analg., December 1, 2008; 107(6): 1783 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schneeweiss, J. D. Seeger, J. Landon, and A. M. Walker Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death N. Engl. J. Med., February 21, 2008; 358(8): 771 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Bridges Valid Comparisons of Antifibrinolytic Agents Used in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2790 - 2792. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Mannucci and M. Levi Prevention and Treatment of Major Blood Loss N. Engl. J. Med., May 31, 2007; 356(22): 2301 - 2311. [Full Text] [PDF]
|
|
|
|
|
|
V. A. Ferraris, C. R. Bridges, R. P. Anderson, for the Blood Conservation Guideline, J. R. Brown, N. J.O. Birkmeyer, G. T. O'Connor, J. H. Levy, J. G. Ramsay, R. A. Guyton, et al. Aprotinin in cardiac surgery. N. Engl. J. Med., May 4, 2006; 354(18): 1953 - 1957. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Cooper Jr, J. Abrams, O.H. Frazier, R. Radovancevic, B. Radovancevic, A. W. Bracey, M. J. Kindo, and I. D. Gregoric Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: Possible association with antifibrinolytic therapy J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 963 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Camarasa, G. Olle, M. Serra-Prat, A. Martin, M. Sanchez, P. Ricos, A. Perez, and L. Opisso Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial Br. J. Anaesth., May 1, 2006; 96(5): 576 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dial, E. Delabays, M. Albert, A. Gonzalez, J. Camarda, A. Law, and D. Menzies Hemodilution and surgical hemostasis contribute significantly to transfusion requirements in patients undergoing coronary artery bypass J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 654 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Belway, F D Rubens, D Wozny, B Henley, and H J Nathan Are we doing everything we can to conserve blood during bypass? A national survey Perfusion, September 1, 2005; 20(5): 237 - 241. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Shander, D. Moskowitz, and T. S. Rijhwani The Safety and Efficacy of "Bloodless" Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2005; 9(1): 53 - 63. [Abstract] [PDF]
|
|
|
|
|
|
A. M. Mahdy and N. R. Webster Perioperative systemic haemostatic agents Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Moskowitz, J. J. Klein, A. Shander, K. M. Cousineau, R. S. Goldweit, C. Bodian, S. I. Perelman, H. Kang, D. A. Fink, H. C. Rothman, et al. Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center Ann. Thorac. Surg., February 1, 2004; 77(2): 626 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Smith, S. K. Datta, L. H. Muhlbaier, G. Samsa, A. Nadel, and J. Lipscomb Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials Ann. Thorac. Surg., February 1, 2004; 77(2): 635 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Shore-Lesserson, D. L. Reich, and D. H. Adams Invited commentary Ann. Thorac. Surg., February 1, 2004; 77(2): 642 - 643. [Full Text] [PDF]
|
|
|
|
|
|
A. Koster, S. Huebler, F. Merkle, T. Hentschel, M. Grundel, T. Krabatsch, L. Tambeur, M. Praus, H. Habazettl, W. M. Kuebler, et al. Heparin-Level-Based Anticoagulation Management During Cardiopulmonary Bypass: A Pilot Investigation on the Effects of a Half-Dose Aprotinin Protocol on Postoperative Blood Loss and Hemostatic Activation and Inflammatory Response Anesth. Analg., February 1, 2004; 98(2): 285 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Greilich, C. F. Brouse, C. W. Whitten, L. Chi, J. M. DiMaio, and M. E. Jessen Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of {epsilon}-aminocaproic acid and aprotinin J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1498 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Scott, F. C. Seifert, P. S. A. Glass, and R. Grimson Blood Use in Patients Undergoing Coronary Artery Bypass Surgery: Impact Of Cardiopulmonary Bypass Pump, Hematocrit, Gender, Age, and Body Weight Anesth. Analg., October 1, 2003; 97(4): 958 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Karski and J. T. Balatbat Blood Conservation Strategies in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 175 - 188. [Abstract] [PDF]
|
|
|
|
|
|
G. A. Nuttall, D. N. Fass, L. J. Oyen, W. C. Oliver Jr., and M. H. Ereth A Study of a Weight-Adjusted Aprotinin Dosing Schedule During Cardiac Surgery Anesth. Analg., February 1, 2002; 94(2): 283 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Thielmeier, J. R. Pank, R. D. Dowling, and L. A. Gray JR Anesthetic and Perioperative Considerations in Patients Undergoing Placement of Totally Implantable Replacement Hearts Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2001; 5(4): 335 - 344. [Abstract] [PDF]
|
|
|
|
|
|
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Greilich, K. Okada, P. Latham, R. R. Kumar, and M. E. Jessen Aprotinin But Not {epsilon}-Aminocaproic Acid Decreases Interleukin-10 After Cardiac Surgery With Extracorporeal Circulation: Randomized, Double-Blind, Placebo-Controlled Study in Patients Receiving Aprotinin and {epsilon}-Aminocaproic Acid Circulation, September 18, 2001; 104 (2009): I-265 - I-269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wajon, J. Gibson, R. Calcroft, C. Hughes, and B. Thrift Intraoperative Plateletpheresis and Autologous Platelet Gel Do Not Reduce Chest Tube Drainage or Allogeneic Blood Transfusion After Reoperative Coronary Artery Bypass Graft Anesth. Analg., September 1, 2001; 93(3): 536 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ray, M. M. Hales, L. Brown, M. F. O'Brien, and E. G. Stafford Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit Ann. Thorac. Surg., August 1, 2001; 72(2): 521 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Fiechtner, G. A. Nuttall, M. E. Johnson, Y. Dong, N. Sujirattanawimol, W. C. Oliver Jr., R. S. Sarpal, L. J. Oyen, and M. H. Ereth Plasma Tranexamic Acid Concentrations During Cardiopulmonary Bypass Anesth. Analg., May 1, 2001; 92(5): 1131 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ray and M. F. O'Brien Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost Ann. Thorac. Surg., March 1, 2001; 71(3): 838 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. East, F. Clements, J. Mathew, and T. F. Slaughter Antiphospholipid Syndrome and Cardiac Surgery: Management of Anticoagulation in Two Patients Anesth. Analg., May 1, 2000; 90(5): 1098 - 1101. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Knutson, J. A. Deering, F. W. Hall, G. A. Nuttall, D. R. Schroeder, R. D. White, and C. J. Mullany Does Intraoperative Hetastarch Administration Increase Blood Loss and Transfusion Requirements After Cardiac Surgery? Anesth. Analg., April 1, 2000; 90(4): 801 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Munoz, N. J.O. Birkmeyer, L. J. Dacey, J. D. Birkmeyer, D. C. Charlesworth, E. R. Johnson, S. J. Lahey, M. Norotsky, R. D. Quinn, B. M. Westbrook, et al. Trends in rates of reexploration for hemorrhage after coronary artery bypass surgery Ann. Thorac. Surg., October 1, 1999; 68(4): 1321 - 1325. [Abstract] [Full Text] [PDF]
|
|